This is a second generation centrally-acting antihypertensive which act as an agonist of the imidazoline I1 receptor in brainstem sympathetic nuclei.
Moxonidine is equally effective in reducing blood pressure as the current standard therapies (thiazides, beta-blockers and calcium antagonists). It is as effective as the first generation centrally-acting antihypertensives but has fewer side-effects.
Post-marketing surveillance reported a low incidence of adverse effects. Headache, dizziness, dry mouth and tiredness have been reported.
The summary of product characteristics should be consulted before prescribing this drug.
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page